A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy

Launched by AALBORG UNIVERSITY HOSPITAL · Jun 24, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two bowel cleansing products, Plenvu® and Picoprep®, to see which one works better and is easier for patients to tolerate before having a colonoscopy. A colonoscopy is a procedure that allows doctors to look inside the large intestine to check for any signs of disease, including cancer. In this trial, 400 patients who are scheduled for a colonoscopy will be randomly assigned to take either Plenvu or Picoprep. They will fill out a questionnaire about their experience with these products, focusing on any side effects they might have felt during the bowel preparation process.

To be eligible for this trial, participants need to be 18 years or older and scheduled for an outpatient colonoscopy. However, certain individuals are not eligible, such as those with severe heart or kidney issues, pregnant or breastfeeding women, and those with specific medical conditions. Throughout the study, doctors who assess how well the bowel has been cleansed will not know which product the patient used, ensuring an unbiased comparison. This trial aims to provide valuable information that can help improve the preparation process for future colonoscopies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ambulant colonoscopy
• • Older than18
• Exclusion Criteria:
• • Younger than 18
• • Known with severe heart failure
• • Known with severe renal failure (eGFR\<30)
• • Known for colonic stenosis
• • Pregnant or breastfeeding
• • Acute colonoscopy
• • Cancer screening program colonoscopy
• • Mentally retarded
• • Redo colonoscopy of patients included in this study and colonoscopy was canceled because of bad bowel preparation.
• • Patients with Phenylketonuria
• • Patients with Glucose-6-phosphate-dehydrogenase deficiency
• • Patients with colon or rectum resection